These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

778 related items for PubMed ID: 17393458

  • 1. Histopathologic and clinical outcome of rituximab treatment in patients with cyclophosphamide-resistant proliferative lupus nephritis.
    Gunnarsson I, Sundelin B, Jónsdóttir T, Jacobson SH, Henriksson EW, van Vollenhoven RF.
    Arthritis Rheum; 2007 Apr; 56(4):1263-72. PubMed ID: 17393458
    [Abstract] [Full Text] [Related]

  • 2. Treatment with cyclophosphamide delays the progression of chronic lesions more effectively than does treatment with azathioprine plus methylprednisolone in patients with proliferative lupus nephritis.
    Grootscholten C, Bajema IM, Florquin S, Steenbergen EJ, Peutz-Kootstra CJ, Goldschmeding R, Bijl M, Hagen EC, Van Houwelingen HC, Derksen RH, Berden JH, Dutch Working Party on Systemic Lupus Erythematosus.
    Arthritis Rheum; 2007 Mar; 56(3):924-37. PubMed ID: 17328070
    [Abstract] [Full Text] [Related]

  • 3. Longterm clinical and immunological effects of anti-CD20 treatment in patients with refractory systemic lupus erythematosus.
    Lindholm C, Börjesson-Asp K, Zendjanchi K, Sundqvist AC, Tarkowski A, Bokarewa M.
    J Rheumatol; 2008 May; 35(5):826-33. PubMed ID: 18398943
    [Abstract] [Full Text] [Related]

  • 4. Immunosuppressive therapy in lupus nephritis: the Euro-Lupus Nephritis Trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide.
    Houssiau FA, Vasconcelos C, D'Cruz D, Sebastiani GD, Garrido Ed Ede R, Danieli MG, Abramovicz D, Blockmans D, Mathieu A, Direskeneli H, Galeazzi M, Gül A, Levy Y, Petera P, Popovic R, Petrovic R, Sinico RA, Cattaneo R, Font J, Depresseux G, Cosyns JP, Cervera R.
    Arthritis Rheum; 2002 Aug; 46(8):2121-31. PubMed ID: 12209517
    [Abstract] [Full Text] [Related]

  • 5. Is combination rituximab with cyclophosphamide better than rituximab alone in the treatment of lupus nephritis?
    Li EK, Tam LS, Zhu TY, Li M, Kwok CL, Li TK, Leung YY, Wong KC, Szeto CC.
    Rheumatology (Oxford); 2009 Aug; 48(8):892-8. PubMed ID: 19478041
    [Abstract] [Full Text] [Related]

  • 6. Treatment of refractory SLE with rituximab plus cyclophosphamide: clinical effects, serological changes, and predictors of response.
    Jónsdóttir T, Gunnarsson I, Risselada A, Henriksson EW, Klareskog L, van Vollenhoven RF.
    Ann Rheum Dis; 2008 Mar; 67(3):330-4. PubMed ID: 17827182
    [Abstract] [Full Text] [Related]

  • 7. Predictors and outcome of renal flares after successful cyclophosphamide treatment for diffuse proliferative lupus glomerulonephritis.
    Mok CC, Ying KY, Tang S, Leung CY, Lee KW, Ng WL, Wong RW, Lau CS.
    Arthritis Rheum; 2004 Aug; 50(8):2559-68. PubMed ID: 15334470
    [Abstract] [Full Text] [Related]

  • 8. Repeated renal biopsy in proliferative lupus nephritis--predictive role of serum C1q and albuminuria.
    Gunnarsson I, Sundelin B, Heimbürger M, Forslid J, van Vollenhoven R, Lundberg I, Jacobson SH.
    J Rheumatol; 2002 Apr; 29(4):693-9. PubMed ID: 11950009
    [Abstract] [Full Text] [Related]

  • 9. Anti-CD20 therapy in patients with refractory systemic lupus erythematosus: a longitudinal analysis of 52 Hispanic patients.
    Garcia-Carrasco M, Mendoza-Pinto C, Sandoval-Cruz M, Soto-Vega E, Beltran-Castillo A, Jimenez-Hernandez M, Graillet D, Gonzalez L, Rojas-Rodriguez J, Pineda-Almazana A, Zamudio-Huerta L, Lopez-Colombo A.
    Lupus; 2010 Feb; 19(2):213-9. PubMed ID: 19965944
    [Abstract] [Full Text] [Related]

  • 10. Early response to immunosuppressive therapy predicts good renal outcome in lupus nephritis: lessons from long-term followup of patients in the Euro-Lupus Nephritis Trial.
    Houssiau FA, Vasconcelos C, D'Cruz D, Sebastiani GD, de Ramon Garrido E, Danieli MG, Abramovicz D, Blockmans D, Mathieu A, Direskeneli H, Galeazzi M, Gül A, Levy Y, Petera P, Popovic R, Petrovic R, Sinico RA, Cattaneo R, Font J, Depresseux G, Cosyns JP, Cervera R.
    Arthritis Rheum; 2004 Dec; 50(12):3934-40. PubMed ID: 15593207
    [Abstract] [Full Text] [Related]

  • 11. Remission of proliferative lupus nephritis following B cell depletion therapy is preceded by down-regulation of the T cell costimulatory molecule CD40 ligand: an open-label trial.
    Sfikakis PP, Boletis JN, Lionaki S, Vigklis V, Fragiadaki KG, Iniotaki A, Moutsopoulos HM.
    Arthritis Rheum; 2005 Feb; 52(2):501-13. PubMed ID: 15693003
    [Abstract] [Full Text] [Related]

  • 12. Rituximab therapy for childhood-onset systemic lupus erythematosus.
    Willems M, Haddad E, Niaudet P, Koné-Paut I, Bensman A, Cochat P, Deschênes G, Fakhouri F, Leblanc T, Llanas B, Loirat C, Pillet P, Ranchin B, Salomon R, Ulinski T, Bader-Meunier B, French Pediatric-Onset SLE Study Group.
    J Pediatr; 2006 May; 148(5):623-627. PubMed ID: 16737873
    [Abstract] [Full Text] [Related]

  • 13. B-cell depletion in the treatment of patients with systemic lupus erythematosus: a longitudinal analysis of 24 patients.
    Leandro MJ, Cambridge G, Edwards JC, Ehrenstein MR, Isenberg DA.
    Rheumatology (Oxford); 2005 Dec; 44(12):1542-5. PubMed ID: 16188950
    [Abstract] [Full Text] [Related]

  • 14. Long-term outcome of diffuse proliferative lupus glomerulonephritis treated with cyclophosphamide.
    Mok CC, Ying KY, Ng WL, Lee KW, To CH, Lau CS, Wong RW, Au TC.
    Am J Med; 2006 Apr; 119(4):355.e25-33. PubMed ID: 16564783
    [Abstract] [Full Text] [Related]

  • 15. Health-related quality of life and treatment burden in patients with proliferative lupus nephritis treated with cyclophosphamide or azathioprine/ methylprednisolone in a randomized controlled trial.
    Grootscholten C, Snoek FJ, Bijl M, van Houwelingen HC, Derksen RH, Berden JH, Dutch Working Party of SLE.
    J Rheumatol; 2007 Aug; 34(8):1699-707. PubMed ID: 17659757
    [Abstract] [Full Text] [Related]

  • 16. Rituximab in the treatment of resistant lupus nephritis: therapy failure in rapidly progressive crescentic lupus nephritis.
    Davies RJ, Sangle SR, Jordan NP, Aslam L, Lewis MJ, Wedgwood R, D'Cruz DP.
    Lupus; 2013 May; 22(6):574-82. PubMed ID: 23632989
    [Abstract] [Full Text] [Related]

  • 17. [Significance of serum anti-Clq Ab in evaluation of lupus nephritis activity and its curative effects of pharmacotherapy on lupus nephritis].
    Cai XY, Yang XY, Chen XH, Liang LQ, Guan MM, Qin SG, Fu JZ.
    Zhonghua Yi Xue Za Zhi; 2004 Sep 02; 84(17):1436-9. PubMed ID: 15500738
    [Abstract] [Full Text] [Related]

  • 18. A retrospective seven-year analysis of the use of B cell depletion therapy in systemic lupus erythematosus at University College London Hospital: the first fifty patients.
    Lu TY, Ng KP, Cambridge G, Leandro MJ, Edwards JC, Ehrenstein M, Isenberg DA.
    Arthritis Rheum; 2009 Apr 15; 61(4):482-7. PubMed ID: 19333973
    [Abstract] [Full Text] [Related]

  • 19. Longterm followup of childhood lupus nephritis.
    Hagelberg S, Lee Y, Bargman J, Mah G, Schneider R, Laskin C, Eddy A, Gladman D, Urowitz M, Hebert D, Silverman E.
    J Rheumatol; 2002 Dec 15; 29(12):2635-42. PubMed ID: 12465165
    [Abstract] [Full Text] [Related]

  • 20. Intensive short-term treatment with rituximab, cyclophosphamide and methylprednisolone pulses induces remission in severe cases of SLE with nephritis and avoids further immunosuppressive maintenance therapy.
    Roccatello D, Sciascia S, Rossi D, Alpa M, Naretto C, Baldovino S, Menegatti E, La Grotta R, Modena V.
    Nephrol Dial Transplant; 2011 Dec 15; 26(12):3987-92. PubMed ID: 21385860
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 39.